Who should receive EGFR tyrosine-kinase inhibitors?

Lancet Oncol. 2012 Nov;13(11):1074-6. doi: 10.1016/S1470-2045(12)70434-5. Epub 2012 Oct 16.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Erlotinib Hydrochloride
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Protein Kinase Inhibitors / administration & dosage*
  • Quinazolines / administration & dosage*

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride